Tenaya Therapeutics Stock
Tenaya Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Faraz Ali
- Employees
- 70
- Market cap
- $85 M
- IPO
- 30/07/2021
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial;…
Tenaya Therapeutics stock: price history
1D
-6.8%
1W
-34.4%
1M
-42.1%
6M
-51.3%
YTD
-46.5%
1Y
-79.5%
2Y
-78.2%
5Y
-98.1%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~1% stronger price swings than usual
Ask the agents about Tenaya Therapeutics
Analyst assessment of Tenaya Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$2.33
MEDIAN
US$2.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 12/03/2026
Tenaya Therapeutics stock metrics
P/E
-0.72
P/B
1.19
EV/EBITDA
-0.12
RETURN ON EQUITY
-62.5%
NET MARGIN
-3,909.3%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.4%
FLOAT SHARES
211,720,220
AVG. DAILY VOLUME (30D)
3,595,859
Insider transactions (SEC)
Tingley Whittemore
Ali Faraz
Tingley Whittemore
Tingley Whittemore
Tingley Whittemore
Institutional holders
Comparable stocks
Frequently asked questions about Tenaya Therapeutics stock
What does Tenaya Therapeutics do?
Tenaya Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Faraz Ali, the company employs around 70 people.
The IPO was on 30/07/2021; the stock trades on NASDAQ under the ticker TNYA.
What do analysts say about Tenaya Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 12/03/2026).
The average price target is US$2.33, ranging from US$2.00 to US$3.00, with a median of US$2.00.
This is an external assessment, not a statement by Market Jury.
When does Tenaya Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Tenaya Therapeutics pay a dividend?
No, Tenaya Therapeutics currently does not pay a dividend.
Which stocks are comparable to Tenaya Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tenaya Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tenaya Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.